xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

435

ICAR SINONASAL TUMORS

1559. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol . 2015;16(4):375-384. https://doi.org/10.1016/S1470 2045(15)70076-8 1560. Butler M, Hamid O, Ribas A, et al. Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies. Eur J Cancer . 2017;72(Suppl. 1):S123. 1561. Hamid O, Ribas A, Stephen Hodi F, et al. Efficacy of pem brolizumab (pembro) in patients (pts) with advanced mucosal melanoma (mucMEL): data from KEYNOTE-001, 002, and 006. Pigment Cell Melanoma Res . 2017;30(1):102. https://doi. org/10.1111/pcmr.12547 1562. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol . 2015;16(8):908-918. https://doi.org/10. 1016/S1470-2045(15)00083-2 Finegersh A, et al. Immunotherapy in sinonasal melanoma: treat ment patterns and outcomes compared to cutaneous melanoma. Int Forum Allergy Rhinol . 2020;10(9):1087-1095. https://doi.org/10.1002/alr.22628 1564. Lechner M, Takahashi Y, Turri-Zanoni M, et al. Interna tional multicenter study of clinical outcomes of sinonasal melanoma shows survival benefit for patients treated with immune checkpoint inhibitors and potential improvements to the current TNM staging system. J Neurol Surg B Skull Base . 2023;84(4):307-319. https://doi.org/10.1055/s-0042-1750178 1565. Abiri A, Yasaka TM, Lehrich BM, et al. Adjuvant therapy and prognosticators of survival in head and neck mucosal melanoma. Laryngoscope . 2022;132(3):584-592. https://doi. org/10.1002/lary.29807 1566. Medina JE, Ferlito A, Pellitteri PK, et al. Current management of mucosal melanoma of the head and neck. J Surg Oncol . 2003;83(2):116-122. https://doi.org/10.1002/jso.10247 1567. Manolidis S, Donald PJ. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer . 1997;80(8):1373-1386. https://doi.org/10.1002/%28SICI%291097-0142%2819971015% 2980:8%3C1373::AID-CNCR3%3E3.0.CO;2-G 1568. Amit M, Tam S, Abdelmeguid AS, et al. Approaches to regional lymph node metastasis in patients with head and neck mucosal melanoma. Cancer . 2018;124(3):514-520. https:// doi.org/10.1002/cncr.31083 1569. Baptista P, Garcia Velloso MJ, Salvinelli F, Casale M. Radio guided surgical strategy in mucosal melanoma of the nasal cavity. Clin Nucl Med . 2008;33(1):14-18. https://doi.org/10. 1097/RLU.0b013e31815c5092 1570. Starek I, Koranda P, Benes P. Sentinel lymph node biopsy: a new perspective in head and neck mucosal melanoma? Melanoma Res . 2006;16(5):423-427. https://doi.org/10.1097/01. cmr.0000222603.57932.b6 1571. Oldenburg MS, Price DL. The utility of sentinel node biopsy for sinonasal melanoma. J Neurol Surg B Skull Base . 2017;78(5):425-429. https://doi.org/10.1055/s-0037-1603960 1563. Klebaner D, Saddawi-Konefka R,

1545. Guo L, Zhang H, Chen B. Nivolumab as programmed death 1 (PD-1) inhibitor for targeted immunotherapy in tumor. J Cancer . 2017;8(3):410-416. https://doi.org/10.7150/jca.17144 1546. Kashat L, Le CH, Chiu AG. The role of targeted therapy in the management of sinonasal malignancies. Otolaryngol Clin North Am . 2017;50(2):443-455. https://doi.org/10.1016/j. otc.2016.12.016 1547. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med . 2012;366(26):2443-2454. https://doi.org/10.1056/ NEJMoa1200690 1548. Topalian SL, Sznol M, McDermott DF, et al. Sur vival, durable tumor remission, and long-term safety in patients with advanced melanoma receiv ing nivolumab. J Clin Oncol . 2014;32(10):1020-1030. https://doi.org/10.1200/JCO.2013.53.0105 1549. Klemen ND, Wang M, Rubinstein JC, et al. Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma. J Immunother Cancer . 2020;8(1):e000341. https:// doi.org/10.1136/jitc-2019-000341 1550. D’Angelo SP, Larkin J, Sosman JA, et al. Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis. J Clin Oncol . 2017;35(2):226-235. https://doi.org/10.1200/JCO. 2016.67.9258 1551. Hodi FS, Chapman PB, Sznol M, et al. Safety and effi cacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218). Melanoma Res . 2021;31(1):67-75. 1552. Topalian SL, Hodi FS, Brahmer JR, et al. Five-year survival and correlates among patients with advanced melanoma, renal cell carcinoma, or non-small cell lung cancer treated with nivolumab. JAMAOncol . 2019;5(10):1411-1420. https://doi.org/ 10.1001/jamaoncol.2019.2187 1553. Baetz TD, Fletcher GG, Knight G, et al. Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: a systematic review. Cancer Treat Rev . 2020;87:102032. https:// doi.org/10.1016/j.ctrv.2020.102032 1554. Rutkowski P, Kozak K. News from the melanoma sessions of the European Cancer Congress 2017. BMCMed . 2017;15(1):57. https://doi.org/10.1186/s12916-017-0826-4 1555. Hodi FS, O’Day SJ, McDermott DF, et al. Improved sur vival with ipilimumab in patients with metastatic melanoma. N Engl J Med . 2010;363(8):711-723. https://doi.org/10.1056/ NEJMoa1003466 1556. Schadendorf D, Hodi FS, Robert C, et al. Pooled analysis of long-term survival data from phase II and phase III tri als of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol . 2015;33(17):1889-1894. https://doi.org/10.1200/ JCO.2014.56.2736 1557. Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mecha nisms and clinical management. Scientifica . 2013;2013:857519. https://doi.org/10.1155/2013/857519 1558. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. NEngl JMed . 2015;372(4):320-330. https://doi.org/10.1056/NEJMoa1412082